Researchers Find Biomarker Tied to Severity of Ulcerative Colitis
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 18, 2024 -- For patients with ulcerative colitis, the HLA-DRB1*01:03 allele is associated with severe ulcerative colitis, according to a research letter published online Oct. 15 in the Journal of the American Medical Association to coincide with the United European Gastroenterology Week, held from Oct. 12 to 15 in Vienna.
Marie Vibeke Vestergaard, from Aalborg University in Denmark, and colleagues conducted a Danish nationwide genome-wide association study on severe versus less severe ulcerative colitis to identify biomarkers using data from a combined cohort of 4,491 patients (4,153 from the neonatal blood spot cohort [NBS] and 338 from the North Denmark Biobank study [NorDIBD]).
The researchers found that a chromosome 6 locus within the HLA region was significantly associated with severe versus less severe ulcerative colitis from 9,508,878 tested single-nucleotide variations (odds ratio, 2.23). The HLA-DRB1*01:03 allele explained this association (odds ratio, 3.32 overall; 3.29 for NBS and 3.98 for NorDIBD). No other allele had a P value below the genome-wide significance threshold. The association with the HLA-DRB1*01:03 allele had odds ratios of 6.38, 5.24, and 2.30 for major operation, at least two hospitalizations, and use of at least 5,000 mg of systemic corticosteroids for carriers versus noncarriers. For carriers versus noncarriers, the hazard ratios were 2.22, 5.13, and 1.69 for time to hospitalization, time to major operation, and time to first treatment with systemic corticosteroids, respectively.
"Given the low cost of typing a single HLA allele, HLA-DRB1*01:03 could be a valuable tool for risk assessment of patients with ulcerative colitis at diagnosis," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-19 06:00
Read more
- Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer
- Metformin Beneficial in Lung Cancer Patients With Overweight, Obesity
- Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
- 1 in 20 Pregnant U.S. Women Face Emotional, Physical Abuse
- FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
- FDA Approves Simplified Dosing Regimen for Acetadote (N-acetylcysteine for injection)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions